A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 183,900 shares of RCUS stock, worth $2.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
183,900
Previous 82,400 123.18%
Holding current value
$2.68 Million
Previous $1.25 Million 124.16%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$13.69 - $18.01 $1.39 Million - $1.83 Million
101,500 Added 123.18%
183,900 $2.81 Million
Q2 2024

Aug 09, 2024

SELL
$14.59 - $18.48 $2.31 Million - $2.92 Million
-158,100 Reduced 65.74%
82,400 $1.25 Million
Q1 2024

May 13, 2024

BUY
$14.83 - $20.18 $1.74 Million - $2.36 Million
117,000 Added 94.74%
240,500 $4.54 Million
Q4 2023

Feb 13, 2024

SELL
$13.43 - $19.63 $259,199 - $378,859
-19,300 Reduced 13.52%
123,500 $2.36 Million
Q3 2023

Nov 14, 2023

BUY
$17.62 - $23.54 $2.52 Million - $3.36 Million
142,800 New
142,800 $2.56 Million
Q3 2021

Nov 12, 2021

SELL
$26.93 - $37.68 $7.42 Million - $10.4 Million
-275,700 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$22.75 - $35.77 $427,700 - $672,476
18,800 Added 7.32%
275,700 $7.57 Million
Q1 2021

May 13, 2021

BUY
$26.16 - $41.39 $6.72 Million - $10.6 Million
256,900 New
256,900 $7.21 Million
Q2 2020

Aug 13, 2020

SELL
$13.97 - $36.56 $3.65 Million - $9.56 Million
-261,416 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$8.78 - $19.28 $387,882 - $851,751
44,178 Added 20.34%
261,416 $3.63 Million
Q4 2019

Feb 13, 2020

BUY
$7.33 - $10.79 $560,012 - $824,355
76,400 Added 54.25%
217,238 $2.19 Million
Q3 2019

Nov 13, 2019

BUY
$6.44 - $10.18 $684,172 - $1.08 Million
106,238 Added 307.05%
140,838 $1.28 Million
Q2 2019

Aug 12, 2019

BUY
$7.29 - $13.38 $252,234 - $462,948
34,600 New
34,600 $275,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.05B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.